Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $10.11 USD
Change Today -0.14 / -1.37%
Volume 18.1K
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

innocoll ag-spon adr (INNL) Snapshot

Open
$10.22
Previous Close
$10.25
Day High
$10.40
Day Low
$10.00
52 Week High
04/24/15 - $10.46
52 Week Low
10/14/14 - $4.45
Market Cap
220.4M
Average Volume 10 Days
52.9K
EPS TTM
$-27.90
Shares Outstanding
21.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INNOCOLL AG-SPON ADR (INNL)

Related News

No related news articles were found.

innocoll ag-spon adr (INNL) Related Businessweek News

No Related Businessweek News Found

innocoll ag-spon adr (INNL) Details

Innocoll AG, a specialty pharmaceutical company, manufactures and sells collagen-based pharmaceutical products and devices in Europe, the Middle East, Asia, and the United States. The company’s products comprise CollaGUARD, a transparent bioresorbable collagen film for the prevention of post-operative adhesions in various surgical applications, including digestive, colorectal, gynecological, and urological surgeries in open and laparoscopic approaches; Collatamp Gentamicin surgical implant for the treatment or prevention of post-operative infection; Septocoll, a bioresorbable dual-action collagen sponge for the treatment or prevention of post-operative infection; and RegenePro, a bioresorbable collagen sponge for dental applications. Its products also include XaraColl, an implantable and bioresorbable collagen sponge that is in phase III clinical trials for the treatment of post-operative pain relief; and Cogenzia, a topically applied bioresorbable collagen sponge, which is in phase III efficacy trials for the treatment of diabetic foot infections. The company is headquartered in Athlone, Ireland.

83 Employees
Last Reported Date: 04/23/15

innocoll ag-spon adr (INNL) Top Compensated Officers

Chief Executive Officer and Member of Managem...
Total Annual Compensation: $32.4K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: $464.6K
Head of Portfolio Operations
Total Annual Compensation: $619.8K
Compensation as of Fiscal Year 2014.

innocoll ag-spon adr (INNL) Key Developments

Innocoll AG Announces the Results of Pharmacokinetic Study

Innocoll AG announced that the results of a pharmacokinetic (PK) study support using a dose of 300 mg of XaraColl, Innocoll's collagen/bupivacaine bioresorbable implant, in its planned Phase 3 studies to evaluate the efficacy of XaraColl in the treatment of post-operative pain. The 62-patient PK study had 3 main objectives: to evaluate the PK profile of 200 mg and 300 mg doses of XaraColl compared to a 150 mg bupivacaine HCl injection in patients undergoing open laparotomy hernioplasty; to document maximal systemic levels (Cmax) of bupivacaine; and to evaluate the preliminary safety and tolerability of XaraColl treatment. The study confirmed proportional systemic levels of bupivacaine for both the 200 mg and 300 mg dose XaraColl implants. The maximal mean serum concentrations (Cmax) were below levels that would be expected to result in systemic toxic effects. A preliminary review of safety observations in connection with the PK study suggested both doses were well tolerated.

Innocoll AG Secures EUR 25 Million Loan Commitment from European Investment Bank

Innocoll AG announced the securing of a credit facility for up to EUR 25 million of debt financing to support the expansion of the company's manufacturing and research and development facility in Saal Germany and clinical development of the company's lead product candidates, XaraColl, Cogenzia and CollaGUARD. The debt financing, which Innocoll AG entered into together with its subsidiary, Innocoll Pharmaceuticals Limited, is provided by the European Investment Bank. The EIB loan commitment of EUR 25 million is comprised of EUR 15 million tranche which can be drawn in whole or in part at any time up to June, 2016, and a EUR 10 million tranche which can be drawn subject to either of the company's Phase 3 trials for XaraColl or Cogenzia meeting the required primary end points, at any time up to September 2016. The loan has a five year maturity, and an interest rate of 12% per annum, compounded annually. Interest accrues during the term of the loan and is payable only at maturity, and principal is repaid in a single bullet payment at maturity, resulting in no cash payments required during the five year term of the loan. The loan may be repaid by Innocoll early at any time or could be required to be prepaid early by EIB in certain circumstances, in each case subject to a 1% or lower repayment indemnity.

Innocoll AG Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Innocoll AG reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported revenue of EUR 755,000 compared to EUR 834,000 a year ago. This increase was primarily due to an increase in sales to Jazz Pharmaceuticals of CollatampG of EUR 0.7 million, or 26%, and an increase in CollaGUARD sales of EUR 0.2 million, or 131%, primarily due to the first shipment of the company adhesion barrier CollaGUARD to the company partner Takeda in connection with the product's launch in Russia in the third quarter of 2014. Loss from operating activities –continuing operations was EUR 6,324,000 compared to EUR 2,535,000 a year ago. Loss before income tax was EUR 4,192,000 compared to EUR 4,562,000 a year ago. Loss attributable to equity holders of the company was EUR 4,237,000 compared to EUR 4,581,000 a year ago. Diluted loss per share was EUR 2.9 compared to diluted loss per share of EUR 118.2 a year ago. Non-GAAP net loss was EUR 4,237,000 compared to EUR 4,581,000 a year ago. For the nine months period, the company reported revenue of EUR 4,497,000 compared to EUR 3,546,000 a year ago. Loss from operating activities –continuing operations was EUR 16,054,000 compared to EUR 4,408,000 a year ago. Loss before income tax was EUR 20,514,000 compared to profit before income tax of EUR 2,181,000 a year ago. Loss attributable to equity holders of the company was EUR 20,666,000 compared to EUR 2,109,000 a year ago. Diluted loss per share was EUR 28.1 compared to EUR 9.5 a year ago. Non-GAAP net losses were EUR 9,252,000 compared to net earnings of EUR 2,314,000 a year ago. Net cash used in operating activities was EUR 12,700,000 compared to EUR 4,677,000 a year ago. Purchases of property, plant and equipment were EUR 909,000 compared to EUR 448,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INNL:US $10.11 USD -0.14

INNL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $69.43 USD +0.69
Durect Corp $2.20 USD +0.23
Sanofi €91.20 EUR -0.36
View Industry Companies
 

Industry Analysis

INNL

Industry Average

Valuation INNL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 35.9x
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 34.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INNOCOLL AG-SPON ADR, please visit www.innocollinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.